The role of CYP2D6 and TaqI a polymorphisms in malignant neuroleptic syndrome: Two case reports with three episodes

Psychiatria Danubina

Volumn 22, Issue 1, 2010, Pages 112-116

  Živković, Maja ^a   Mihaljević Peleš, Alma ^b   Sǎgud, Marina ^b   Silić, Ante ^c   Mihanović, Mate ^c  

^a Neuropsihijatrijska bolnica   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

^c Zagreb Fakultet za dentalnu medicinu i zdravstvo Osijek Zdravstveno veleu ili te Zagreb   (Croatia)

Author keywords

Antipsychotic drugs; CYP2D6 polymorphism; Malignant neuroleptic syndrome (MNS); TaqI A DRD2 polymorphism

Indexed keywords

CLOZAPINE; CYTOCHROME P450 2D6; DIAZEPAM; DOPAMINE 2 RECEPTOR; FLUPHENAZINE; HALOPERIDOL; LITHIUM CARBONATE; LORAZEPAM; PERAZINE; PROMAZINE; QUETIAPINE; TAQ POLYMERASE; TAQ1 A; UNCLASSIFIED DRUG; VALPROIC ACID; DIBENZOTHIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; ALLELE; CASE REPORT; CLINICAL FEATURE; CONFERENCE PAPER; DISEASE PREDISPOSITION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LABORATORY TEST; MALE; NEUROLEPTIC MALIGNANT SYNDROME; PATHOPHYSIOLOGY; PHARMACOGENETICS; PHENOTYPE; ARTICLE; BIPOLAR DISORDER; DRUG COMBINATION; GENETICS; HETEROZYGOTE DETECTION; PSYCHOSIS; RECURRENT DISEASE;

ADULT; ALLELES; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CLOZAPINE; CYTOCHROME P-450 CYP2D6; DIBENZOTHIAZEPINES; DRUG THERAPY, COMBINATION; FLUPHENAZINE; GENOTYPE; HALOPERIDOL; HETEROZYGOTE DETECTION; HUMANS; LITHIUM CARBONATE; MALE; NEUROLEPTIC MALIGNANT SYNDROME; PERAZINE; POLYMORPHISM, GENETIC; PSYCHOTIC DISORDERS; RECEPTORS, DOPAMINE D2; RECURRENCE; RISPERIDONE;

EID: 77954631723     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (31)

1. Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T: Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004; 65:464-470.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition. Washington D.C., 1994.
3. Berardi D, Amore M, Keck PE Jr, Troia M, Dell'Atti M: Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: case control study. Biol Psychiatry 1998; 44:748-754. (Pubitemid 28496791)
4. Bottlender R, Jäger M, Hofschuster E, Dobmeier P, Möller HJ: Neuroleptic malignant syndrome due to atypical neuroleptics: three episodes in one patient. Pharmacopsychiatry 2002; 35:119-21. (Pubitemid 34651920)
5. Caroff SN, Mann SC, McCarthy M, Naser J, Rynn M, Morrison M: Acute infectious encephalitis complicated by neuroleptic malignant syndrome. J Clin Psychopharmacol 1998; 18:349-351. (Pubitemid 28353884)
6. Cohen SA: Successful clozapine rechallenge following prior intolerance to clozapine. J Clin Psychiatry 1994; 55:498-9.
7. Delay J, Deniker P: Drug-induce extrapyramidal syndrome. Handbook of Clinical Neurology. Visken PJ, Bruyn GW (eds). Oxford, North-Holland Publishing Co, 1968, pp 258-266.
8. Deuschel G, Oepen G, Hermle L, Kindt H: Neuroleptic malignant syndrome: observations on altered consciousness. Pharmacopsychiatry 1987; 20:168-170. (Pubitemid 17120490)
9. Foster A, Wang Z, Usman M, Stirewalt E, Buckley P: Pharmacogenetics of antipsychotic adverse effects: Case studies and literature review for clinicians. Neuropsychiatric Disease and Treatment 2007; 6:965-973.
10. Haddad PM and Dursun SM: Neurological complications of psychiatric drugs: clinical features and management. Hum Psychopharmacol Clin Exp. 2008; 23:15-26. (Pubitemid 351166609)
11. Hosty G: Neuroleptic malignant syndrome in two sisters. Irish J Psychol Med 1992; 9:122-123.
12. Huang TL: Neuroleptic malignant syndrome associated with long-term clozapine treatment: report of a case and results of a clozapine rechallenge. Chang Gung Med J 2001; 24:522-5.
13. Illing M, Ancill R: Clozapine-induced neuroleptic malignant syndrome: clozapine monotherapy rechallenge in a case of previous NMS. Can J Psychiatry 1996; 41:258. (Pubitemid 26189263)
14. Itoh H, Ohtsuka N, Ogita K, Yagi G, Miura S, Koga Y: Malignant neuroleptic syndrome: its present status in Japan and clinical problems: Folia Psychiatr Neurol Jpn 1977; 31: 565-575.
15. Iwahashi K: CYP2D6 genotype and possible susceptibility to neuroleptic malignant syndrome. Biol Psychiatry 1994; 36:780-782.
16. Kato D, Kawanishi C, Kishida I, Furuno T, Matsumura T, Hasegawa H, Suzuki K, Hirayasu Y: CYP2D6 gene deletion allele in patients with neuroleptic malignant syndrome: preliminary report. Psychiatry Clin Neurosci 2005; 59:504-507. (Pubitemid 41139561)
17. Kato D, Kawanishi C, Kishida I, Furuno T, Suzuki K, Onishi H, Hirayasu Y: Effects of CYP2D6 polymorphisms on neuroleptic malignant syndrome. Eur J Clin Pharmacol 2007; 63:991-996. (Pubitemid 47561803)
18. Keck PE Jr, Pope HG Jr, Cohen BM, McElroy SL, Nierenberg AA: Risk factors for neuroleptic malignant syndrome: a case-control study. Arch Gen Psychiatry 1989; 46:914-918. (Pubitemid 19259539)
19. Kishida I, Kawanishi C, Furuno T, Matsumura T, Hasegawa H, Sugiyama N, Suzuki K, Yamada Y, Kosaka K: Lack of association in Japanese patients between neuroleptic malignant syndrome and the TaqI A polymorphism of the dopamine D2 receptor gene. Psychiatr Genet 2003; 13:55-57. (Pubitemid 36293147)
20. Lavie CJ, Ventura HO, Walker G: Neuroleptic malignant syndrome: three episodes with different drugs. South Med J 1986; 79:1571-3.
21. Mathews T, Aderibigbe YA: Proposed research diagnostic criteria for neuroleptic malignant syndrome. Int J Neuropsychopharmacol 1999; 2:129-144.
22. Michalets EM: Update: Clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998; 18: 84-112.
23. Mihaljević-Peleš A, Šagud M, Božina N, Živković M. Pharmacogenetics and antidepressant treatment in integrative psychiatriy perspective. Psychiatria Danubina 2008; 20:3:374-376.
24. Otani K, Horiuchi M, Kondo T, Kaneko S, Fukushima Y: Is the predisposition to neuroleptic malignant syndrome genetically transmitted? Br J Psychiatry 1991; 158:850-853.
25. Paparrigopoulos T, Tzavellas E, Ferentinos P, Mourikis I, Liappas J: Catatonia as a risk factor for the development of neuroleptic malignant syndrome: report of a case following treatment with clozapine. World J Biol Psychiatry 2009; 10:70-73.
26. Pelonero AL, Levenson JL, Pandurangi AK: Neuroleptic malignant syndrome: a review. Psychiatr Serv 1998; 49:1163-72. (Pubitemid 28414680)
27. Pope HG Jr, Keck PE Jr, McElroy SL: Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry 1986; 143:1227-1233.
28. Sachdev P, Mason C, Hadzi-Pavlovic D: Case-control study of neuroleptic malignant syndrome. Am J Psychiatry 1997; 154:1156-1158. (Pubitemid 27328837)
29. Suzuki A, Kondo T, Otani K, Mihara K, Yasui-Furukori N, Sano A, Koshiro K, Kaneko S: Association of the TaqI A polymorphism of the dopamine D2 receptor gene with predisposition to neuroleptic malignant syndrome. Am J Psychiatry 2001; 158:1714-1716. (Pubitemid 32923667)
30. Weller M, Kornhuber J: Clozapine rechallenge after an episode of 'neuroleptic malignant syndrome'. Br J Psychiatry 1992; 161:855-6.
31. Wilkaitis J, Mulvihill T, Nasrallah HA: Classic antipsychotic medications. In: Schatzberg AF, Nemeroff CB eds. American psychiatric publishing textbook of psychopharmacology. 3rd ed. American Psychiatric Publishing. 2004; p 437.